E
EDX Medical Group's AI 'Supertest'
4.7(253 reviews)
A highly accurate AI-driven test analysing over 100 biological markers in blood and urine samples to detect prostate cancer, aiming to revolutionise screening and early detection.
Healthcare AIFreemium
Visit WebsiteKey Features
- 100+ clinically validated biomarkers
- Multi-omics approach analysis
- Blood and urine sample testing
- AI-powered algorithm interpretation
- Early and late-stage cancer detection
- Genetic/hereditary risk assessment
- Aggressive vs slow cancer identification
- Multi-ethnic group accuracy
Pros
- 96-99% sensitivity & specificity
- Non-invasive testing
- High-risk group detection
- Patent filed with EPO
- Cambridge-developed technology
Cons
- Awaiting MHRA/FDA approval
- Launch expected late 2025/early 2026
- Primarily UK focused initially
- Professional administration required
